肝窦阻塞综合征发病机制及其生物标志物研究进展

摘要/Abstract

摘要： 肝窦阻塞综合征(HSOS)是一种复杂而严重的肝血管疾病,常见于应用含有吡咯里西啶生物碱(PA)的植物、化疗药物和细胞毒药物,以及骨髓造血干细胞移植后。本文探讨了PA导致的HSOS的多因素发病机制,包括药物直接毒性、血栓形成、炎症激活等,并结合组学技术分析HSOS的分子病理学特征和研究进展,阐述潜在生物标志物。部分生物标志物有望用于早期诊断和治疗监测。未来,更加契合临床实际需求的HSOS个体化治疗策略将充分整合这些研究进展,特别是多组学信息,以实现更精准的干预和更好的患者预后。

关键词: 肝窦阻塞综合征, 肝小静脉闭塞病, 生物标志物, 多组学研究, 发病机制, 病理特征

马屹凡, 高虹. 肝窦阻塞综合征发病机制及其生物标志物研究进展[J]. 肝脏, 2024, 29(6): 735-739.

/ 推荐

参考文献

[1] 柯子良,刘玉兰. 肝窦阻塞综合征研究进展[J]. 中华肝脏病杂志,2022,30(12):1298-1303.
[2] Xiao Y, Yu TJ, Xu Y. Emerging therapies in cancer metabolism[J]. Cell Metab, 2023,35(8):1283-1303.
[3] Augsornworawat P, Hogrebe N J, Ishahak M. Single-nucleus multi-omics of human stem cell-derived islets identifies deficiencies in lineage specification[J]. Nat Cell Biol, 2023,25(6):904-916.
[4] 中华医学会消化病学分会肝胆疾病协作组. 吡咯生物碱相关肝窦阻塞综合征诊断和治疗专家共识意见(2017年,南京)[J].中华消化杂志, 2017,37(8): 513-522.
[5] Coppell J A, Brown S A, Perry D J. Veno-occlusive disease: cytokines, genetics, and haemostasis[J]. Blood Rev, 2003, 17(2):63-70.
[6] Yang M, Ruan J, Fu P P. Cytotoxicity of pyrrolizidine alkaloid in human hepatic parenchymal and sinusoidal endothelial cells: firm evidence for the reactive metabolites mediated pyrrolizidine alkaloid-induced hepatotoxicity[J]. Chem Biol Interact, 2016, 243:119-126.
[7] Plessier A, Rautou P E, Valla D C. Management of hepatic vascular diseases[J]. J Hepatol, 2012, 56 Suppl 1:S25-S38.
[8] Yu X Z, Ji T, Bai X L. Expression of MMP-9 in hepatic sinusoidal obstruction syndrome induced by Gynura segetum[J]. J Zhejiang Univ Sci B, 2013, 14(1):68-75.
[9] Robinson S M, Mann D A, Manas D M. The potential contribution of tumour-related factors to the development of FOLFOX-induced sinusoidal obstruction syndrome[J]. Br J Cancer, 2013, 109(9):2396-2403.
[10] Marzano C, Cazals-Hatem D, Rautou P E. The significance of nonobstructive sinusoidal dilatation of the liver: Impaired portal perfusion or inflammatory reaction syndrome[J]. Hepatology, 2015, 62(3):956-963.
[11] Zhang F, Zhou Y, Yang X. Gynura Rhizoma containing pyrrolizidine alkaloids induces the hepatic sinusoidal obstruction syndrome in mice via upregulating fibrosis-related factors[J]. Acta Pharmacol Sin, 2019, 40(6):781-789.
[12] Zhu L, Zhang C Y, Li D P. Tu-San-Qi (Gynura japonica): the culprit behind pyrrolizidine alkaloid-induced liver injury in China[J]. Acta Pharmacol Sin, 2021, 42(8):1212-1222.
[13] Yang M, Ruan J, Gao H. First evidence of pyrrolizidine alkaloid N-oxide-induced hepatic sinusoidal obstruction syndrome in humans[J]. Arch Toxicol, 2017, 91(12):3913-3925.
[14] Yang X, Wang H, Ni H M. Inhibition of Drp1 protects against senecionine-induced mitochondria-mediated apoptosis in primary hepatocytes and in mice[J]. Redox Biol, 2017, 12:264-273.
[15] Augsornworawat P, Hogrebe N J, Ishahak M. Single-nucleus multi-omics of human stem cell-derived islets identifies deficiencies in lineage specification[J]. Nat Cell Biol, 2023, 25(6):904-916.
[16] Ott J, Wang J, Leal S M. Genetic linkage analysis in the age of whole-genome sequencing[J]. Nat Rev Genet, 2015, 16(5):275-284.
[17] Xiao Y, Yu T J, Xu Y. Emerging therapies in cancer metabolism[J]. Cell Metab, 2023, 35(8):1283-1303.
[18] Ebmeyer J, Behrend J, Lorenz M. Pyrrolizidine alkaloid-induced alterations of prostanoid synthesis in human endothelial cells[J]. Chem Biol Interact, 2019, 298:104-111.
[19] Li Y, Porta-Pardo E, Tokheim C. Pan-cancer proteogenomics connects oncogenic drivers to functional states[J]. Cell, 2023,186(18):3921-3944.e25.
[20] Benson M D, Eisman A S, Tahir U A. Protein-metabolite association studies identify novel proteomic determinants of metabolite levels in human plasma[J]. Cell Metab, 2023, 35(9):1646-1660.e3.
[21] Savarese D M, Savy G, Vahdat L. Prevention of chemotherapy and radiation toxicity with glutamine[J]. Cancer Treat Rev, 2003,29(6):501-513.
[22] Shi J, Dhaliwal P, Zi Zheng Y. An intact ACTH LC-MS/MS assay as an arbiter of clinically discordant immunoassay results[J]. Clin Chem, 2019, 65(11):1397-1404.
[23] Qiu S, Zhang H, Fei Q. Urine and plasma metabolomics study on potential hepatoxic biomarkers identification in rats induced by Gynura segetum[J]. J Ethnopharmacol, 2018, 216:37-46.
[24] Takeuchi M, Oda S, Tsuneyama K. Comprehensive analysis of serum microRNAs in hepatic sinusoidal obstruction syndrome (SOS) in rats: implication as early phase biomarkers for SOS[J]. Arch Toxicol, 2018, 92(9):2947-2962.
[25] Gupta M, Stenson M, O'Byrne M. Comprehensive serum cytokine analysis identifies IL-1RA and soluble IL-2Rα as predictors of event-free survival in T-cell lymphoma[J]. Ann Oncol, 2016, 27(1):165-172.
[26] Hwang W L, Pike L R G, Royce T J. Safety of combining radiotherapy with immune-checkpoint inhibition[J]. Nat Rev Clin Oncol, 2018, 15(8):477-494.
[27] Wang X, Zhang W, Yang Y. Blood microRNA signatures serve as potential diagnostic biomarkers for hepatic sinusoidal obstruction syndrome caused by gynura japonica containing pyrrolizidine alkaloids[J]. Front Pharmacol, 2021, 12:627126.
[28] Lin G, Wang JY, Li N. Hepatic sinusoidal obstruction syndrome associated with consumption of Gynura segetum[J]. J Hepatol, 2011, 54(4):666-673.
[29] Ehmann H M A, Breitwieser D, Winter S. Gold nanoparticles in the engineering of antibacterial and anticoagulant surfaces[J]. Carbohydr Polym, 2015, 117:34-42.
[30] Villiger L, Grisch-Chan H M, Lindsay H. Treatment of a metabolic liver disease by in vivo genome base editing in adult mice[J]. Nat Med, 2018, 24(10):1519-1525.
[31] Whitfield J B. Meta-analysis of the effects of alcohol dehydrogenase genotype on alcohol dependence and alcoholic liver disease[J]. Alcohol Alcohol, 1997, 32(5):613-619.
[32] Gao H, Ruan J Q, Chen J. Blood pyrrole-protein adducts as a diagnostic and prognostic index in pyrrolizidine alkaloid-hepatic sinusoidal obstruction syndrome[J]. Drug Des Devel Ther, 2015, 9:4861-4868.